Sunho Biologics Inc. (2898)

Overview

Sunho Biologics, Inc. is a biopharmaceutical entity committed to pioneering the development and commercialization of innovative biologics. The focus of the company lies in manipulating the immune microenvironment to benefit treatment outcomes, leveraging both the innate and adaptive immune systems. Founded in 2018 and headquartered in Huzhou, China, Sunho Biologics operates as a subsidiary under Sunho Wisdom Investments Limited. Their work primarily targets various cancers and autoimmune diseases, progressing through different stages of clinical trials to ensure the efficacy and safety of their biotherapeutic solutions.

Products and Services

• IAH0968: This enhanced monoclonal antibody specializes in antibody-dependent cell-mediated cytotoxicity, undergoing Phase II clinical trials. Designed to target biliary tract carcinoma and colorectal cancer (CRC), IAH0968 represents Sunho Biologics’ commitment to addressing hard-to-treat cancers through advanced immunotherapy.

• IAP0971 and IAE0972 immunocytokines: These immunocytokines have completed Phase I clinical trials, showcasing their potential in treating advanced solid tumors, including non-small cell lung cancer and CRC. Their development underscores Sunho Biologics' strategy to innovate in the realm of cancer immunotherapy.

• Preclinical Stage Products: The company’s pipeline also features several preclinical stage products aiming at solid tumors and immune response regulation, including:

  • IBB0979: An immunocytokine for solid tumors.
  • IBC0966: An anti-PD-L1 antibody-signal regulatory protein bifunctional fusion protein for inducing tumor-specific immune responses.
  • IBD0333: Targeted at tumor cells for enhanced cancer therapy.
  • IAN0982: Focused on oncology applications.
  • ISH0988 and ISH0613: Immunossuppressors dedicated to various autoimmune diseases, aiming to modulate the immune response safely.